Submission Details
| 510(k) Number | K172913 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 25, 2017 |
| Decision Date | January 12, 2018 |
| Days to Decision | 109 days |
| Submission Type | Traditional |
| Review Panel | Hematology (HE) |
| Summary | Summary PDF |
K172913 is an FDA 510(k) clearance for the cobas Factor II and Factor V Test, a Test, Factor Ii G20210a Mutations, Genomic Dna Pcr (Class II — Special Controls, product code NPR), submitted by Roche Molecular Systems, Inc. (Pleasanton, US). The FDA issued a Cleared decision on January 12, 2018, 109 days after receiving the submission on September 25, 2017. This device falls under the Hematology review panel. Regulated under 21 CFR 864.7280.
| 510(k) Number | K172913 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 25, 2017 |
| Decision Date | January 12, 2018 |
| Days to Decision | 109 days |
| Submission Type | Traditional |
| Review Panel | Hematology (HE) |
| Summary | Summary PDF |
| Product Code | NPR — Test, Factor Ii G20210a Mutations, Genomic Dna Pcr |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 864.7280 |
| Definition | In Vitro Diagnostic Test To Detect The Factor Ii G20210a Mutation In Genomic Dna, As An Aid To Diagnosis In The Evaluation Of Patients With Suspected Thrombophilia. |